Literature DB >> 19948621

Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease.

Yu-Cheng Lin1, Pi-Feng Chang, Fu-Chang Hu, Mei-Hwei Chang, Yen-Hsuan Ni.   

Abstract

OBJECTIVE: Oxidative stress is increased in nonalcoholic fatty liver disease (NAFLD). Variants in the UGT1A1 gene contribute to increased bilirubin levels, and bilirubin can act as an antioxidant. We hypothesize that variant UGT1A1 genotypes reduce the risk for NAFLD development.
METHODS: Two hundred thirty-four obese children 6 to 13 years of age were recruited. NAFLD was determined through liver ultrasonography. The UGT1A1 genotypes UGT1A1*6 and UGT1A1*28 were detected. We assessed the effects of UGT1A1 genotypes on pediatric NAFLD.
RESULTS: In total, 12% of the obese children had NAFLD. The subjects with NAFLD had lower serum total bilirubin levels (0.25 +/- 0.30 mg/dL) than did those without NAFLD (0.36 +/- 0.38 mg/dL; P = .021). With conditioning on the effects of age- and gender-adjusted BMI, waist/hip ratio, and adiponectin levels, variant UGT1A1*6 genotypes were a protecting factor for NAFLD, with an estimated adjusted odds ratio of 0.31 (95% confidence interval: 0.11-0.91; P = .033), but variant UGT1A1*28 genotypes were not significantly associated with the occurrence of NAFLD.
CONCLUSIONS: Variant UGT1A1*6 genotypes are associated with a lower risk of NAFLD in obese Taiwanese children. The UGT1A1 genotype is a new risk factor for pediatric NAFLD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19948621     DOI: 10.1542/peds.2008-3087

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  25 in total

1.  Heme oxygenase-1 gene promoter polymorphism and the risk of pediatric nonalcoholic fatty liver disease.

Authors:  P-F Chang; Y-C Lin; K Liu; S-J Yeh; Y-H Ni
Journal:  Int J Obes (Lond)       Date:  2015-04-03       Impact factor: 5.095

Review 2.  Bilirubin in the Liver-Gut Signaling Axis.

Authors:  Abdul-Rizaq Hamoud; Lauren Weaver; David E Stec; Terry D Hinds
Journal:  Trends Endocrinol Metab       Date:  2018-02-03       Impact factor: 12.015

Review 3.  Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach.

Authors:  Anna Alisi; Ariel E Feldstein; Alberto Villani; Massimiliano Raponi; Valerio Nobili
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-01-17       Impact factor: 46.802

Review 4.  The Genetics of Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Nidhi P Goyal; Jeffrey B Schwimmer
Journal:  Clin Liver Dis       Date:  2017-10-05       Impact factor: 6.126

5.  GWAS of butyrylcholinesterase activity identifies four novel loci, independent effects within BCHE and secondary associations with metabolic risk factors.

Authors:  Beben Benyamin; Rita P Middelberg; Penelope A Lind; Anne M Valle; Scott Gordon; Dale R Nyholt; Sarah E Medland; Anjali K Henders; Andrew C Heath; Pamela A F Madden; Peter M Visscher; Daniel T O'Connor; Grant W Montgomery; Nicholas G Martin; John B Whitfield
Journal:  Hum Mol Genet       Date:  2011-08-23       Impact factor: 6.150

Review 6.  Biliverdin reductase and bilirubin in hepatic disease.

Authors:  Lauren Weaver; Abdul-Rizaq Hamoud; David E Stec; Terry D Hinds
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-03-01       Impact factor: 4.052

Review 7.  Genetic determinants of hepatic steatosis in man.

Authors:  Amanda J Hooper; Leon A Adams; John R Burnett
Journal:  J Lipid Res       Date:  2011-01-18       Impact factor: 5.922

8.  Does bilirubin prevent hepatic steatosis through activation of the PPARα nuclear receptor?

Authors:  Terry D Hinds; Samuel O Adeosun; Abdulhadi A Alamodi; David E Stec
Journal:  Med Hypotheses       Date:  2016-08-31       Impact factor: 1.538

9.  Loss of biliverdin reductase-A promotes lipid accumulation and lipotoxicity in mouse proximal tubule cells.

Authors:  Samuel O Adeosun; Darren M Gordon; Mary Frances Weeks; Kyle H Moore; John E Hall; Terry D Hinds; David E Stec
Journal:  Am J Physiol Renal Physiol       Date:  2018-04-04

Review 10.  Bilirubin as a metabolic hormone: the physiological relevance of low levels.

Authors:  Justin F Creeden; Darren M Gordon; David E Stec; Terry D Hinds
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-12-07       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.